Impact of CYP2D6 genotype and co-medication with paroxetine and clarithromycin on clomiphene metabolism in vivo

被引：0
|
作者：
Muerdter, T. [1 ,2 ]
Lehr, T. [3 ]
Igel, S. [1 ,2 ]
Kroener, P. [1 ,2 ]
Ganchev, B. [1 ,2 ]
Schaeffeler, E. [1 ,2 ]
Boehmer, G. [4 ]
Sonnenberg, M. [1 ,2 ]
Brauch, H. [1 ,2 ]
Kerb, R. [1 ,2 ]
Schwab, M. [1 ,2 ,4 ]
机构：
[1] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany
[2] Univ Tubingen, Stuttgart, Germany
[3] Univ Saarland, Klin Pharm, Saarbrucken, Germany
[4] Univ Klinikum Tubingen, Klin Pharmakol Abt, Tubingen, Germany
来源：
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY | 2016年 / 389卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
021
引用
收藏
页码：S8 / S8
页数：1
相关论文
共 50 条
  • [41] The impact of CYP2D6 genotypes on the plasma concentration of paroxetine in Japanese psychiatric patients
    Ueda, M
    Hirokane, G
    Morita, S
    Okawa, M
    Watanabe, T
    Akiyama, K
    Shimoda, K
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2006, 30 (03): : 486 - 491
  • [42] Influence of CYP2D6 genotype and medication on the sparteine metabolic ratio of psychiatric patients
    P. Lohmann
    M. Rao
    M. Ludwig
    E. Griese
    U. Zanger
    K. Mörike
    W. Maier
    M. Bagli
    European Journal of Clinical Pharmacology, 2001, 57 : 289 - 295
  • [43] Influence of CYP2D6 genotype and medication on the sparteine metabolic ratio of psychiatric patients
    Lohmann, PL
    Rao, ML
    Ludwig, M
    Griese, EU
    Zanger, UM
    Mörike, K
    Maier, W
    Bagli, M
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 57 (04) : 289 - 295
  • [44] The effect of CYP 2D6 genotype and CYP2D6 inhibitors on tamoxifen
    Stearns, V
    Hayes, DF
    Jin, Y
    Ullmer, L
    Nguyen, A
    Storniolo, AM
    Flockhart, U
    Desta, Z
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 5S - 5S
  • [45] Impact of CYP2D6*2, CYP2D6*35, rs5758550, and related haplotypes on risperidone clearance in vivo
    Storset, Elisabet
    Braten, Line Skute
    Ingelman-Sundberg, Magnus
    Johansson, Inger
    Molden, Espen
    Kringen, Marianne Kristiansen
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 80 (10) : 1531 - 1541
  • [46] Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers
    Özdemir, V
    Tyndale, RF
    Reed, K
    Herrmann, N
    Sellers, EM
    Kalow, W
    Naranjo, CA
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1999, 19 (05) : 472 - 475
  • [47] Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol (vol 72, pg 175, 2016)
    Patteet, Lisbeth
    Haufroid, Vincent
    Maudens, Kristof
    Sabbe, Bernard
    Morrens, Manuel
    Neels, Hugo
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 73 (01) : 127 - 127
  • [48] Does ethnicity impact CYP2D6 genotype-phenotype relationships?
    Frederiksen, Trine
    Areberg, Johan
    Schmidt, Ellen
    Stage, Tore Bjerregaard
    Brosen, Kim
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 16 (06): : 1012 - 1020
  • [49] Is there an impact of CYP2D6 genotype on the toxicity of 'ecstasy' and related designer drugs?
    Schwab, M
    Griese, U
    Hermle, L
    Gouzoulis, E
    Zanger, U
    Mikus, G
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 357 (04) : R163 - R163
  • [50] The Impact of the CYP2D6 "Enhancer" Single Nucleotide Polymorphism on CYP2D6 Activity
    Dinh, Jean C.
    Boone, Erin C.
    Staggs, Vincent S.
    Pearce, Robin E.
    Wang, Wendy Y.
    Gaedigk, Roger
    Leeder, James Steven
    Gaedigk, Andrea
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 (03) : 646 - 654
12345